01—Abstract
Summary
Summary of the 8-K filed May 28, 2026. Cited figures are marked; the original filing is the authoritative source.
Teva Pharmaceutical Industries Limited reported the results of its Annual Meeting of shareholders, held on May 28, 2026, in this Item 5.07 filing.
Shareholders elected Dr. Sol J. Barer to the Board to serve until Teva's 2029 annual meeting. The filing reports 627,816,662 votes for, 245,921,571 against, 530,682 abstentions and 50,661,570 broker non-votes for his election.
Shareholders also approved, on a non-binding advisory basis, the compensation of Teva's named executive officers as disclosed in the proxy statement. That proposal received 795,976,042 votes for, 77,082,847 against, 1,170,026 abstentions and 50,661,570 broker non-votes. The advisory vote favored approval, though the filing reports against votes of 77,082,847.
Finally, shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until the 2027 annual meeting. That proposal received 880,542,242 votes for, 36,085,507 against, 525,382 abstentions and no broker non-votes.
02—Key points
Key Highlights
- Shareholders elected Dr. Sol J. Barer to the Board, to serve until the 2029 annual meeting, with 627,816,662 votes for and 245,921,571 against.
- Shareholders approved, on a non-binding advisory basis, the compensation of named executive officers, with 795,976,042 votes for and 77,082,847 against.
- Shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as independent registered public accounting firm until the 2027 annual meeting, with 880,542,242 votes for and 36,085,507 against.
- The auditor appointment received the strongest support of the three proposals, with 525,382 abstentions and zero broker non-votes reported.
- The filing reports 50,661,570 broker non-votes on both the director election and the advisory compensation vote.
03—Questions
Frequently Asked Questions
What matters did Teva's shareholders vote on at the May 28, 2026 Annual Meeting?
Shareholders voted on the election of Dr. Sol J. Barer to the Board, a non-binding advisory vote on named executive officer compensation, and the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as independent registered public accounting firm.
Who was elected to Teva's Board at the Annual Meeting, and for how long?
Dr. Sol J. Barer was elected to the Board to serve until Teva's 2029 annual meeting of shareholders. The filing reports 627,816,662 votes for, 245,921,571 against, and 530,682 abstentions for his election.
Did shareholders approve the compensation of Teva's named executive officers?
Yes. Shareholders approved, on a non-binding advisory basis, the compensation of the named executive officers listed in the proxy statement. The filing reports 795,976,042 votes for, 77,082,847 against, and 1,170,026 abstentions.
Who is Teva's independent registered public accounting firm after this vote?
Shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until the 2027 annual meeting of shareholders. The filing reports 880,542,242 votes for, 36,085,507 against, and 525,382 abstentions.
04—Continue